U.S. government taps GlaxoSmithKline for new antibiotics
LONDON, May 22 (Reuters) - The U.S. government has signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the dual threats of drug resistance and bioterrorism. The collaboration, the first of its kind between Washington and a drug company, will allow
